Normalizing the Tumor Microenvironment: A New Frontier in Ovarian Cancer Therapy

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Ovarian cancer is one of the deadliest gynecological malignancies, where most patients become clinically symptomatic at advanced stages of disease due to the lack of effective diagnostic screening. Despite recent advances in surgical resection and chemotherapy, recurrent ovarian cancer remains largely refractory to treatment, resulting in poor prognosis. The ovarian cancer tumor microenvironment (TME) is highly abnormal and presents a significant barrier to successful therapy. A combination of abnormal vasculature, desmoplastic extracellular matrix, and aberrantly activated hypoxic and immune-suppressive pathways culminates in promoting tumor growth, dissemination, chemoresistance, and immunosuppression. Whilst immune checkpoint inhibitors have shown success in other cancers, their application in ovarian cancer, particularly at advanced stages, remains limited. In this review, we discussed the application of tumor extracellular matrix normalizing therapies in preclinical models of advanced ovarian cancer, and their synergistic benefit to chemotherapy and immunotherapy. Collectively, these insights underscore TME normalization as a promising therapeutic strategy with the potential to improve ovarian cancer management.
Funding Information
  • National Institute of Neurological Disorders and Stroke (R01-NS126187)
  • National Institute of Neurological Disorders and Stroke (R01-DC020724)
  • Department of Defense New Investigator Award (W81XWH-16-1-0219)
  • Investigator-Initiated Research Award (W81XWH-20-1-0222)
  • Clinical Trial Award (W81XWH2210439)
  • Children’s Tumor Foundation Drug Discovery Initiative
  • Children’s Tumor Foundation Clinical Research Award
  • American Chemical Society (MBGII-24-1255260-01-MBG)

This publication has 112 references indexed in Scilit: